Phenotypes associated with this allele

• Allele Symbol: Tg(Mt1-RET)304Ina
• Allele Name: transgene insertion 304, Izumi Nakashima
• Allele ID: MGI:3039777
• Summary: 7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Ednrb^tm1Ywa/Ednrb^+ Tg(Mt1-RET)304Ina/0	involves: 129S7/SvEvBrd * BALB/c * C57BL/6	MGI:5303093
cx2	Kit^W-v/Kit^W-v Tg(Mt1-RET)304Ina/0	involves: BALB/c * C57BL/6	MGI:5297718
cx3	Kit^W-v/Kit^+ Tg(Mt1-RET)304Ina/0	involves: BALB/c * C57BL/6	MGI:5297719
cx4	Immp2l^Tg(HLA-A/H2-D)2Enge/0 Tg(Mt1-RET)304Ina/0	involves: BALB/c * C57BL/6 * CBA/Ca	MGI:4819158
cx5	Kitl^Sl-d/Kitl^Sl-d Tg(Mt1-RET)304Ina/0	involves: BALB/c * C57BL/6 * DBA/2	MGI:5297720
tg6	Tg(Mt1-RET)304Ina/0	B6.C-Tg(Mt1-RET)304Ina	MGI:4418371
tg7	Tg(Mt1-RET)304Ina/0	involves: BALB/c * C57BL/6	MGI:5297714

Genotype
MGI:5303093

cx1

• Allelic Composition: Ednrb^tm1Ywa/Ednrb⁺; Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: 129S7/SvEvBrd * BALB/c * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:155735 )

• life span after tumor development is shorter than in single Tg(Mt1-RET)304Ina hemizygotes

neoplasm

increased metastatic potential ( J:155735 )

• lung metastasis after tumor development is significantly higher than in Tg(Mt1-RET)304Ina hemizygotes

increased melanoma incidence ( J:155735 )

• melanomagenesis proceeds without a pre-existing benign lesion, indicating de novo melanoma development

• location and shape of tumors is similar to those in single Tg(Mt1-RET)304Ina hemizygotes

• 68.8% of tumors less than 500 mm³ in size are malignant and the rest (31.2%) are premalignant

• 80.8% tumors from mutants are malignant and the rest are premalignant

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
melanoma		DOID:1909		J:155735

Genotype
MGI:5297718

cx2

• Allelic Composition: Kit^W-v/Kit^W-v; Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: BALB/c * C57BL/6

neoplasm

increased melanoma incidence ( J:88074 )

• 8 of 44 mutants develop slowly growing melanocytic tumors and two of these mutants die of melanoma at a late stage

decreased tumor incidence ( J:88074 )

• mutants exhibit suppression of melanoma development compared to single Tg(Mt1-RET)304Ina/0 mice, with only 13.7% of mice developing benign melanocytic tumors and none die by 12 months of age

• mutants are tumor free for up to 13.8 months compared to 3.7 months in single Tg(Mt1-RET)304Ina/0 mice

mortality/aging

premature death ( J:88074 )

• average lifespan of mutants is 15.8 +/- 5.9 months which is not significantly shorter than the mean life span of Kit^W-v homozygotes, but is shorter than wild-type controls

pigmentation

mosaic coat color ( J:88074 )

• mutants have a mosaic of white and black hairs/skin

abnormal melanogenesis ( J:88074 )

• mutants exhibit excess melanogenesis in and around hair bulbs in the area of black hairs/skin

integument

mosaic coat color ( J:88074 )

• mutants have a mosaic of white and black hairs/skin

Genotype
MGI:5297719

cx3

• Allelic Composition: Kit^W-v/Kit⁺; Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: BALB/c * C57BL/6

mortality/aging

decreased tumor-free survival time ( J:88074 )

• average lifespan of mutants with tumors is 13.2 +/- 4.8 months

• 9.8% and 40.9% of mutants die of growing melanoma within 12 and 18 months of birth, respectively

neoplasm

increased melanoma incidence ( J:88074 )

• 68.9% of mutants develop melanocytic tumors

• mutants are on average tumor free until 11.9 months of age

decreased tumor incidence ( J:88074 )

• mutants exhibit suppression of melanoma development compared to single Tg(Mt1-RET)304Ina/0 mice, showing reduced tumor growth and prolonged survival

• 31.1% of mutants do not develop tumors throughout their lifetime

Genotype
MGI:4819158

cx4

• Allelic Composition: Immp2l^{Tg(HLA-A/H2-D)2Enge}/0; Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: BALB/c * C57BL/6 * CBA/Ca

mortality/aging

premature death ( J:130879 )

• CD8+ T cell-depleted mice exhibit shorter survival than CD8+ T cell sufficient mice

neoplasm

increased metastatic potential ( J:130879 )

• in CD8+ T cell-depleted mice compared to in CD8+ T cell sufficient mice

increased tumor incidence ( J:130879 )

• more than 85% of mice develop tumors by 4 months of age with 50% of them exhibiting several evident cutaneous nodules at day 64

• 50% of mice without vitiligo develop visible tumors at 50 days whereas median time for tumor detection in mice with vitiligo is 88 days

increased melanoma incidence ( J:130879 )

• in 95% of mice

increased organ/body region tumor incidence ( J:130879 )

• mice develop tumors on the face earlier than in the posterior part of the body (trunk, tail, leg muscles, or genitals)

increased eye tumor incidence ( J:130879 )

• tumors first appear in the eyes

pigmentation

variable depigmentation ( J:130879 )

• 39% of mice exhibit vitiligo associated with delayed appearance of cutaneous nodules

vision/eye

increased eye tumor incidence ( J:130879 )

• tumors first appear in the eyes

exophthalmos ( J:130879 )

integument

variable depigmentation ( J:130879 )

• 39% of mice exhibit vitiligo associated with delayed appearance of cutaneous nodules

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
melanoma		DOID:1909		J:130879

Genotype
MGI:5297720

cx5

• Allelic Composition: Kitl^Sl-d/Kitl^Sl-d; Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: BALB/c * C57BL/6 * DBA/2

neoplasm

increased melanoma incidence ( J:88074 )

• while fewer mutants develop malanocytic tumors than single Tg(Mt1-RET)304Ina/0 mice, mutants develop more malanocytic tumors than in wild-type controls

decreased tumor incidence ( J:88074 )

• mutants exhibit suppression of melanoma development compared to single Tg(Mt1-RET)304Ina/0 mice, with fewer mutants developing melanocytic tumors and prolonged survival

Genotype
MGI:4418371

tg6

• Allelic Composition: Tg(Mt1-RET)304Ina/0
• Genetic Background: B6.C-Tg(Mt1-RET)304Ina

neoplasm

increased cutaneous melanoma incidence ( J:50392 )

• mice develop benign skin melanocytic tumors that progress to malignant melanomas

• tumors metastasize to the lymph nodes, lung, brain, kidney, liver, and spleen

• Background Sensitivity: tumors are more prevalent on a predominantly C57BL/6 background compared with in mice on a predominantly BALB/c background

• however, mice are tumor free for 100 days

pigmentation

hyperpigmentation ( J:50392 )

• mice exhibit melanosis throughout their life

integument

increased cutaneous melanoma incidence ( J:50392 )

• mice develop benign skin melanocytic tumors that progress to malignant melanomas

• tumors metastasize to the lymph nodes, lung, brain, kidney, liver, and spleen

• Background Sensitivity: tumors are more prevalent on a predominantly C57BL/6 background compared with in mice on a predominantly BALB/c background

• however, mice are tumor free for 100 days

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:50392

Genotype
MGI:5297714

tg7

• Allelic Composition: Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: BALB/c * C57BL/6

mortality/aging

premature death ( J:88074 )

• 70% of mutants die within 12 months after birth of rapidly growing melanoma

• average lifespan of mutants with melanoma is 9.7 +/- 3 months

neoplasm

increased metastatic potential ( J:155735 )

• 43.8% of mutants with malignant tumors (melanoma) exhibit lung metastasis

increased melanoma incidence ( J:155735 )

• mutants develop melanoma via multistep melanomagenesis, beginning with being tumor-free, then benign tumors, premalignant, and malignant stage tumors

• mutants develop solitary or multiple primary dome-shaped tumors on the eyes and skin of the head, neck, trunk, limbs, and tail

• 82.6% of tumors with sizes of less than 500 mm³ are benign and 17.4% are premalignant

• all tumors with sizes of 4,000 mm³ are malignant

• more than 80% of tumors with sizes of 500-4,000 mm³ are premalignant

increased cutaneous melanoma incidence ( J:88074 , J:155735 )

• mutants spontaneously develop melanoma (J:88074)

• mutants show tumors by 3.7 months of age (J:88074)

integument

increased cutaneous melanoma incidence ( J:88074 , J:155735 )

• mutants spontaneously develop melanoma (J:88074)

• mutants show tumors by 3.7 months of age (J:88074)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
melanoma		DOID:1909		J:155735